Los Angeles Capital Management
AUPH icon

Los Angeles Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Los Angeles Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.06M Buy
274,218
+150,732
+122% +$2.2M 0.02% 374
2025
Q4 		$1.5M Buy
+123,486
New +$1.75M 0.01% 516

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Los Angeles Capital Management's AUPH Position: Q1 2026 in Review

Los Angeles Capital Management increased its Aurinia Pharmaceuticals (AUPH) stake by 122% in Q1 2026, buying an estimated $2.2M and bringing the position to 274,218 shares worth $4.06M. The position accounts for 0.02% of the portfolio, ranked #374.

Los Angeles Capital Management first reported a position in AUPH in Q4 2025 and has held it in 2 quarters since. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Los Angeles Capital Management held 274,218 shares of Aurinia Pharmaceuticals worth $4.06M as of Q1 2026.
  • Los Angeles Capital Management bought 150,732 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $2.2M.
  • Aurinia Pharmaceuticals made up 0.02% of Los Angeles Capital Management's portfolio in Q1 2026, its #374 holding.
  • Los Angeles Capital Management first reported a position in Aurinia Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.